Curis opens 11 sites for emavusertib combo in TakeAim CLL trial

Curis has opened enrolment astatine 11 objective sites for its Phase II TakeAim CLL proceedings to measure the oral tiny molecule inhibitor emavusertib, on with zanubrutinib, for patients with chronic lymphocytic leukaemia (CLL).

The institution besides reaffirmed that dosing of the archetypal 5 patients is connected way to instrumentality spot by the extremity of July 2026, with survey information anticipated successful December 2026.

The open-label proceedings volition analyse the dual inhibition strategy targeting atomic origin kappa-light-chain-enhancer of activated B cells (NF-kB), which is considered a cardinal operator successful CLL pathology.

Curis stated that participants are required to beryllium successful a partial effect oregon partial effect with lymphocytosis, indispensable trial arsenic measurable residual illness affirmative utilizing the ClonoSEQ assay and indispensable person been connected zanubrutinib attraction for astatine slightest 12 months.

Curis president and CEO James Dentzer said: "We are pleased with some our operational advancement successful the CLL survey and the beardown enactment from our shareholders arsenic we enactment to regain compliance with the NASDAQ bid terms listing requirement, and we look guardant to gathering connected those successes successful the weeks and months to come."

In parallel, Curis reported stockholder support of a reverse banal divided connection during its peculiar meeting.

At the peculiar meeting, stockholders approved an amendment to the company's Restated Certificate of Incorporation for a reverse banal divided of issued and outstanding shares astatine a ratio betwixt 1-for-5 and 1-for-25.

The company's committee of directors volition find the last ratio. Curis announced its volition to disclose the circumstantial ratio and effectual day earlier the divided is implemented. Shares volition proceed to beryllium traded connected the Nasdaq Capital Market arsenic 'CRIS'.

Curis is besides conducting the TakeAim Lymphoma Phase I/II proceedings of emavusertib with ibrutinib successful relapsed oregon refractory superior cardinal tense strategy lymphoma and has ongoing studies successful acute myeloid leukaemia and myelodysplastic syndromes.

Emavusertib antecedently received orphan cause designation for respective indications from regulatory authorities successful the European Commission and the US.

Curis has an exclusive licence for emavusertib nether a 2015 statement with Aurigene Discovery Technologies.

"Curis opens 11 sites for emavusertib combo successful TakeAim CLL trial" was primitively created and published by Clinical Trials Arena, a GlobalData owned brand.